Answers are grounded in this paper and cite their sources.
We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.
No takes yet. Share an insight, caveat, or question.
Bachelard et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: